Ask AI
ProCE Banner Activity

Efficacy of Switch to DOR/ISL With Baseline RAMs: Retrospective Analysis of 3 Phase III Trials

Conference Coverage
Slideset

In this retrospective analysis of 3 phase III trials of virologically suppressed people living with HIV whose antiretroviral regimens were switched to DOR/ISL, in the presence of baseline RAMs (including TAMs, M184I/V, and/or NNRTI RAMs), virologic suppression was maintained at high levels through Week 96.

Released: July 31, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the International AIDS Society

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

International AIDS Society

ProCE Banner

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions